Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C11H16N2O3S.H2O |
| Molecular Weight | 274.337 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.CC1=CC=C(N2CCNCC2)C(=C1)S(O)(=O)=O
InChI
InChIKey=ZRQKZWAOIRVBFD-UHFFFAOYSA-N
InChI=1S/C11H16N2O3S.H2O/c1-9-2-3-10(11(8-9)17(14,15)16)13-6-4-12-5-7-13;/h2-3,8,12H,4-7H2,1H3,(H,14,15,16);1H2
| Molecular Formula | C11H16N2O3S |
| Molecular Weight | 256.321 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | H2O |
| Molecular Weight | 18.0153 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Caldaret is intracardiac calcium (Ca2+) handling modulator whose cardioprotective actions are presumed to be due to inhibition of the NCX exchanger and increasing the uptake of Ca2+ via the sarcoplasmic reticulum (SR). Unfortunately, Caldaret failed to demonstrate efficacy in Phase II clinical trials as an adjunct to standard therapy with primary percutaneous coronary intervention patients diagnosed as having an acute myocardial infarction
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Effect of caldaret on the incidence of severe left ventricular dysfunction in patients with ST-elevation myocardial infarction undergoing primary coronary intervention. | 2009-01-01 |
|
| Caldaret, an intracellular Ca2+ handling modulator, limits infarct size of reperfused canine heart. | 2007-02 |
|
| Results of the first clinical study of adjunctive CAldaret (MCC-135) in patients undergoing primary percutaneous coronary intervention for ST-Elevation Myocardial Infarction: the randomized multicentre CASTEMI study. | 2006-11 |
|
| A phase II, double-blind, randomized, placebo-controlled, dose comparative study of the efficacy, tolerability, and safety of MCC-135 in subjects with chronic heart failure, NYHA class II/III (MCC-135-GO1 study): rationale and design. | 2004-06 |
|
| Breast-feeding may reduce later blood pressure. | 2004-03-16 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:09:49 GMT 2025
by
admin
on
Mon Mar 31 18:09:49 GMT 2025
|
| Record UNII |
2SH110E854
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID20431256
Created by
admin on Mon Mar 31 18:09:49 GMT 2025 , Edited by admin on Mon Mar 31 18:09:49 GMT 2025
|
PRIMARY | |||
|
DBSALT002435
Created by
admin on Mon Mar 31 18:09:49 GMT 2025 , Edited by admin on Mon Mar 31 18:09:49 GMT 2025
|
PRIMARY | |||
|
192509-24-3
Created by
admin on Mon Mar 31 18:09:49 GMT 2025 , Edited by admin on Mon Mar 31 18:09:49 GMT 2025
|
PRIMARY | |||
|
2SH110E854
Created by
admin on Mon Mar 31 18:09:49 GMT 2025 , Edited by admin on Mon Mar 31 18:09:49 GMT 2025
|
PRIMARY | |||
|
9816981
Created by
admin on Mon Mar 31 18:09:49 GMT 2025 , Edited by admin on Mon Mar 31 18:09:49 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
|
||
|
ANHYDROUS->SOLVATE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|